{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:00:59Z","timestamp":1776801659655,"version":"3.51.2"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["817K166500"],"award-info":[{"award-number":["817K166500"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.neuint.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T16:54:05Z","timestamp":1541782445000},"page":"38-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson's disease model"],"prefix":"10.1016","volume":"122","author":[{"given":"Kazuya","family":"Miyanishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed E.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minori","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madoka","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2981-1013","authenticated-orcid":false,"given":"Masahiro","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2018.11.005_bib1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jphs.2018.03.005","article-title":"Modafinil alleviates levodopa-induced excessive nighttime sleepiness and restores monoaminergic systems in a nocturnal animal model of Parkinson's disease","volume":"136","author":"Ando","year":"2018","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuint.2018.11.005_bib2","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/glia.23199","article-title":"Microglia may compensate for dopaminergic neuron loss in experimental Parkinsonism through selective elimination of glutamatergic synapses from the subthalamic nucleus","volume":"65","author":"Aono","year":"2017","journal-title":"Glia"},{"key":"10.1016\/j.neuint.2018.11.005_bib3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopha.2017.01.123","article-title":"Sesamin imparts neuroprotection against intrastriatal 6-hydroxydopamine toxicity by inhibition of astroglial activation, apoptosis, and oxidative stress","volume":"88","author":"Baluchnejadmojarad","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuint.2018.11.005_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0022-510X(73)90175-5","article-title":"Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations","volume":"20","author":"Bernheimer","year":"1973","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuint.2018.11.005_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0166-2236(03)00038-9","article-title":"Presymptomatic compensation in Parkinson's disease is not dopamine-mediated","volume":"26","author":"Bezard","year":"2003","journal-title":"Trends Neurosci."},{"issue":"2","key":"10.1016\/j.neuint.2018.11.005_bib41","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0306-4522(98)00217-6","article-title":"Biochemical and anatomical characterization of forepaw adjusting steps in rats models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions","volume":"88","author":"Chang","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuint.2018.11.005_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.brainres.2011.02.017","article-title":"Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity","volume":"1384","author":"Choudhury","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2018.11.005_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/brb3.11","article-title":"A cytokine mixture of GM-CSF and IL-3 that induces a neuroprotective phenotype of microglia leading to amelioration of (6-OHDA)-induced Parkinsonism of rats","volume":"1","author":"Choudhury","year":"2011","journal-title":"Brain Behav."},{"key":"10.1016\/j.neuint.2018.11.005_bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/bmj.39289.437454.AD","article-title":"Parkinson's disease","volume":"335","author":"Clarke","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.neuint.2018.11.005_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.09.017","article-title":"Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats","volume":"77","author":"Conti","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2018.11.005_bib10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1126\/science.877576","article-title":"Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity","volume":"197","author":"Creese","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.neuint.2018.11.005_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbr.2011.12.007","article-title":"Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease","volume":"230","author":"Glajch","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuint.2018.11.005_bib12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neuint.2016.06.013","article-title":"The hypnotic bromovalerylurea ameliorates 6-hydroxydopamine-induced dopaminergic neuron loss while suppressing expression of interferon regulatory factors by microglia","volume":"99","author":"Higaki","year":"2016","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuint.2018.11.005_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2005.02.023","article-title":"Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice","volume":"162","author":"Iancu","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuint.2018.11.005_bib14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.bbadis.2017.12.022","article-title":"Sustained anti-inflammatory effects of TGF-beta1 on microglia\/macrophages","volume":"1864","author":"Islam","year":"2018","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuint.2018.11.005_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.neuropharm.2017.02.013","article-title":"A novel GLP-1\/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease","volume":"117","author":"Jalewa","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2018.11.005_bib16","doi-asserted-by":"crossref","first-page":"7669","DOI":"10.1523\/JNEUROSCI.3257-16.2017","article-title":"Alterations in functional cortical hierarchy in hemiparkinsonian rats","volume":"37","author":"Javor-Duray","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuint.2018.11.005_bib17","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.neuint.2018.11.005_bib18","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1523\/JNEUROSCI.20-16-06309.2000","article-title":"Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia","volume":"20","author":"Kim","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuint.2018.11.005_bib19","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nature09159","article-title":"Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry","volume":"466","author":"Kravitz","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.neuint.2018.11.005_bib20","first-page":"6163934","article-title":"Deletion of Herpud1 enhances heme oxygenase-1 expression in a mouse model of Parkinson's disease","volume":"2016","author":"Le","year":"2016","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.neuint.2018.11.005_bib21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuint.2018.11.005_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.expneurol.2005.11.002","article-title":"Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?","volume":"197","author":"Marin","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuint.2018.11.005_bib23","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008870","article-title":"Clinical approach to Parkinson's disease: features, diagnosis, and principles of management","volume":"2","author":"Massano","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuint.2018.11.005_bib24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/mds.21751","article-title":"Glial reactions in Parkinson's disease","volume":"23","author":"McGeer","year":"2008","journal-title":"Mov. Disord. : Official J. Mov. Disord. Soc."},{"key":"10.1016\/j.neuint.2018.11.005_bib25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1460-9568.2005.04238.x","article-title":"The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis","volume":"22","author":"Metz","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuint.2018.11.005_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.58.1.11","article-title":"Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the quality standards subcommittee of the American Academy of Neurology","volume":"58","author":"Miyasaki","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2018.11.005_bib27","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/j.1471-4159.2008.05268.x","article-title":"Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates","volume":"105","author":"Perez","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuint.2018.11.005_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns1001s49","article-title":"Assessment of Parkinson disease manifestations","author":"Perlmutter","year":"2009","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.neuint.2018.11.005_bib29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/mds.24996","article-title":"Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease","volume":"27","author":"Postuma","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2018.11.005_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.neuroscience.2014.11.060","article-title":"Transplantation of fetal ventral mesencephalic progenitor cells overexpressing high molecular weight fibroblast growth factor 2 isoforms in 6-hydroxydopamine lesioned rats","volume":"286","author":"Rumpel","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuint.2018.11.005_bib31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2018.11.005_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"Schwarting","year":"1996","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuint.2018.11.005_bib33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.brainres.2004.03.053","article-title":"High-frequency stimulation of the subthalamic nucleus reverses limb-use asymmetry in rats with unilateral 6-hydroxydopamine lesions","volume":"1013","author":"Shi","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.neuint.2018.11.005_bib34","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.neuropharm.2012.07.029","article-title":"Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease","volume":"63","author":"Sleeman","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2018.11.005_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0306-4522(03)00095-2","article-title":"Basal ganglia efferents to the brainstem centers controlling postural muscle tone and locomotion: a new concept for understanding motor disorders in basal ganglia dysfunction","volume":"119","author":"Takakusaki","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuint.2018.11.005_bib36","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/glia.23315","article-title":"N-myc downstream-regulated gene 2 protects blood-brain barrier integrity following cerebral ischemia","volume":"66","author":"Takarada-Iemata","year":"2018","journal-title":"Glia"},{"key":"10.1016\/j.neuint.2018.11.005_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/mds.10305","article-title":"Systematic review of incidence studies of Parkinson's disease","volume":"18","author":"Twelves","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2018.11.005_bib38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.brainresbull.2008.08.023","article-title":"Evaluation of behavioural effects of a selective NMDA NR1A\/2B receptor antagonist in the unilateral 6-OHDA lesion rat model","volume":"78","author":"Warraich","year":"2009","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuint.2018.11.005_bib39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jneumeth.2004.10.004","article-title":"Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease","volume":"144","author":"Yuan","year":"2005","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuint.2018.11.005_bib40","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0166-2236(90)90112-N","article-title":"Compensations after lesions of central dopaminergic neurons: some clinical and basic implications","volume":"13","author":"Zigmond","year":"1990","journal-title":"Trends Neurosci."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018618302870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018618302870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T21:56:25Z","timestamp":1544478985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018618302870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":41,"alternative-id":["S0197018618302870"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2018.11.005","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson's disease model","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}